Rs12416605:C>T in MIR938 associates with gastric cancer through affecting the regulation of the CXCL12 chemokine gene by Torruella Loran, Ignasi et al.
Mol Genet Genomic Med. 2019;7:e832.    |  1 of 13
https://doi.org/10.1002/mgg3.832
wileyonlinelibrary.com/journal/mgg3
Received: 8 February 2019 | Revised: 23 May 2019 | Accepted: 31 May 2019
DOI: 10.1002/mgg3.832  
O R I G I N A L  A R T I C L E
rs12416605:C>T in MIR938 associates with gastric cancer 
through affecting the regulation of the CXCL12 chemokine gene
Ignasi Torruella‐Loran1 |   María Karla Ramirez Viña2,3 |   Daniela Zapata‐Contreras2,3 |   
Xavier Muñoz4,5 |   Eva Garcia‐Ramallo1 |   Catalina Bonet6 |   Carlos A. Gonzalez6 |   
Núria Sala4,6 |   Yolanda Espinosa‐Parrilla1,2,3  |   on behalf of the EPIC gastric cancer 
working group
1Department of Experimental and Health Sciences, IBE, Institute of Evolutionary Biology (Universitat Pompeu Fabra‐CSIC), Barcelona, Spain
2School of Medicine, Universidad de Magallanes, Punta Arenas, Chile
3Laboratory of Molecular Medicine ‐ LMM, Center for Education, Healthcare and Investigation ‐ CADI, Universidad de Magallanes, Punta Arenas, Chile
4Molecular Epidemiology Group, Translational Research Laboratory, Catalan Institute of Oncology‐IDIBELL, Barcelona, Spain
5Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain
6Unit of Nutrition, Environment and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology‐Bellvitge Biomedical Research Institute 
(ICO‐IDIBELL), Barcelona, Spain
This is an open access article under the terms of the Creat ive Commo ns Attri bution-NonCo mmercial License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited and is not used for commercial purposes.
© 2019 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
Correspondence
Yolanda Espinosa‐Parrilla, School of 
Medicine, Universidad de Magallanes, 




“la Caixa” Foundation, Grant/Award 
Number: BM06-130-0; European Regional 
Development Fund, Grant/Award Number: 
PI070130 and PI12/01187; Ministerio 
de Ciencia e Innovación, Grant/Award 
Number: BFU2010-18477; Fondo de 
Fomento al Desarrollo Científico y 
Tecnológico, Grant/Award Number: 
FONDECYT 1170446; Instituto de Salud 
Carlos III
Abstract
Background: MicroRNAs are small regulatory RNAs with important roles in car-
cinogenesis. Genetic variants in these regulatory molecules may contribute to dis-
ease. We aim to identify allelic variants in microRNAs as susceptibility factors to 
gastric cancer using association studies and functional approaches.
Methods: Twenty‐one single nucleotide variants potentially functional, because of 
their location in either the seed, mature or precursor region of 22 microRNAs, were 
selected for association studies. Genetic association with gastric cancer in 365 cases 
and 1,284 matched controls (European Prospective Investigation into Cancer and 
Nutrition Cohort) was analysed using logistic regression. MicroRNA overexpres-
sion, transcriptome analysis, and target gene validation experiments were performed 
for functional studies.
Results: rs3746444:T>C, in the seed of MIR499A and mature MIR499B, associated 
with the cardia adenocarcinoma location; rs12416605:C>T, in the seed of MIR938, 
associated with the diffuse subtype; and rs2114358:T>C, in the precursor MIR1206, 
associated with the noncardia phenotype. In all cases, the association was inverse, 
indicating a protective affect against gastric cancer of the three minor allelic variants. 
MIR499 rs3746444:T>C and MIR1206 rs2114358:T>C are reported to affect the 
expression of these miRNAs, but the effect of MIR938 rs12416605:C>T is unknown 
yet. Functional approaches showed that the expression of MIR938 is affected by 
rs12416605:C>T and revealed that MIR938 could regulate a subset of cancer‐related 
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1 |  INTRODUCTION
Gastric Cancer (GC) or stomach cancer is the fifth most com-
mon cancer in the world in terms of incidence and the third 
leading cause of cancer death in both sexes worldwide (Ferlay 
et al., 2015; Globocan, 2018). There are two main locations 
of gastric adenocarcinoma: proximal (cardia) and distal (non-
cardia); histologically there are two subtypes of the disease, 
the intestinal‐type, which presents clearly defined glandu-
lar structures, and the undifferentiated diffuse‐type, which 
consists of individually infiltrating neoplastic cells (Crew & 
Neugut, 2006). GC is a multifactorial disease, whose major 
risk factors are environmental, such as Helicobacter pylori 
infection, diet or tobacco, as well as genetic (González, Sala, 
& Rokkas, 2013). Several GC susceptibility genes have al-
ready been identified by both candidate gene analysis and ge-
nome‐wide association studies, among which there are genes 
involved in immunoinflammatory response, DNA repair, cel-
lular adherence, proliferative processes, mucosa protection, 
and Helicobacter pylori's cellular signaling pathways (Loh et 
al., 2009; McLean & El‐Omar, 2014; Saeki, Ono, Sakamoto, 
& Yoshida, 2013; Sala et al., 2012). A multistep model of 
carcinogenesis involving the effects of common low pene-
trance and rare disease‐causing variants is currently accepted 
for GC (Correa, 1992; Fletcher & Houlston, 2010). Once the 
gastric adenocarcinoma has appeared, its prognosis is highly 
dependent on the progression and metastasis of the tumor, 
which are intricate processes partially controlled by onco-
genes and tumor suppressor genes, whose expression is fur-
ther regulated by microRNAs (miRNAs) (Esquela‐Kerscher 
& Slack, 2006).
MiRNAs are nonprotein‐coding small RNAs that neg-
atively regulate the gene expression posttranscriptionally 
(Bartel, 2009). The action of miRNAs as gene repressors is 
performed by means of partial complementarity to miRNA‐
binding sites at their target messenger RNAs (mRNAs) 
resulting in either degradation of the target mRNAs or inhibi-
tion of translation (Filipowicz, Bhattacharyya, & Sonenberg, 
2008). Each mRNA can be repressed by multiple miRNAs, 
as well as each miRNA is a potential regulator of hundreds of 
transcripts (Friedman, Farh, Burge, & Bartel, 2009; Lewis, 
Shih, Jones‐Rhoades, Bartel, & Burge, 2003) accordingly, it 
has been estimated that more than half of the total human 
protein‐coding genes are regulated by miRNAs through com-
plex regulatory networks that control almost every cellular 
processes, including development, differentiation, prolifera-
tion and apoptosis, and having important roles in carcinogen-
esis (Friedman et al., 2009; Kloosterman & Plasterk, 2006; ). 
Aberrant miRNA expression has been related to the diagnosis 
and stage of many types of cancer and numerous studies val-
idate their prognostic and predictive value (Lu et al., 2005; 
Shen, Stass, & Jiang, 2013). In GC various miRNAs have 
been found differentially expressed between tumor and nor-
mal tissues and some of them are associated with the progres-
sion and prognosis of GC, being proposed as potential GC 
biomarkers (Katada et al., 2009; Lu et al., 2005; Shen et al., 
2013; Zhou et al., 2015).
Genetic association studies have pointed to several miRNA 
allelic variants as susceptibility factors to GC (Espinosa‐
Parrilla et al., 2014; Peng et al., 2010; Xia et al., 2016; Yang 
et al., 2014). Nevertheless, very little is known about the real 
contribution of these genetic variants to GC pathology. One 
of the few exceptions is a report showing that the A allele 
of rs11671784 in the MIR27A reduces the expression of the 
miRNA and is associated with a reduction in the risk of GC 
(Yang et al., 2014). A better understanding of the role of sin-
gle‐nucleotide variants (SNVs) in miRNAs in the regulation 
of gastric carcinogenesis could be useful to assess individual 
susceptibility to GC and to evaluate their functional relevance 
and potential use as diagnostic and therapy tools.
In this work, we analysed the genetic association be-
tween GC and 21 SNVs selected because of their location 
in functional miRNA regions in a cohort of 365 cases and 
1,284 healthy controls from the European Prospective 
Investigation into Cancer and Nutrition (EPIC) cohort. We 
found associations between different GC subtypes and three 
SNVs: rs3746444:T>C in the seed of MIR499A and ma-
ture MIR499B, rs12416605:C>T in the seed of MIR938, 
and rs2114358:T>C in the precursor sequence of MIR1206. 
Moreover, we performed functional analyses based on 
genes in an allele‐specific fashion. Furthermore, we demonstrated that CXCL12, a 
chemokine participating in gastric cancer metastasis, is specifically regulated by only 
one of the rs12416605:C>T alleles.
Conclusion: rs12416605 appears to be involved in gastric cancer by affecting the 
regulatory function of MIR938 on genes related to this cancer type, particularly on 
CXCL12 posttranscriptional regulation.
K E Y W O R D S
functional SNV, gastric cancer, gene regulation, genetic susceptibility, microRNA
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miRNA overexpression experiments, transcriptome anal-
yses and target gene‐validation tests, and concluded that 
rs12416605:T>C alters the regulatory action of MIR938 spe-
cifically by affecting the regulation of CXCL12, a chemokine 
gene involved in the etiology of GC.
2 |  MATERIALS AND METHODS
2.1 | Ethical compliance
Patient recruitment, consent, and DNA extraction were car-
ried out as previously described (Riboli et al., 2002). Signed 
informed consent was obtained from all the individuals prior 
to their participation in the study. The study was approved by 
ethics committees at the International Agency for Research 
on Cancer and in each of the EPIC recruitment centers. This 
study conforms to the Declaration of Helsinki standards for 
Medical research involving human subjects.
2.2 | Subjects
Study subjects were selected from the EPIC cohort accord-
ing to a nested case–control design aimed at assessing the 
genetic and environmental risk factors for GC (EurGast 
study). The EPIC cohort has been extensively presented 
(Riboli et al., 2002). Briefly, it includes 521,457 individu-
als recruited between 1992 and 2000 in 23 centers from 
10 North to South European countries. As previously re-
ported (Espinosa‐Parrilla et al., 2014), GC Cases were sub-
jects with adenocarcinoma of the stomach (code C16 of the 
International Classification of Diseases, 10th Revision) hav-
ing blood collected and diagnosed during the follow‐up. An 
independent panel of pathologists confirmed and validated 
the diagnosis, tumor subsite, and morphology (Carneiro et 
al., 2007). Prevalent tumors, cancer located in gastric stump, 
as well as tumors other than adenocarcinoma were excluded. 
For each case, up to four control subjects matched by center, 
gender, age (±2.5  years), and date of blood collection 
(±45 days) were randomly selected among cohort members 
who were alive and free of cancer at the time of diagnosis. 
The initial study population consisted of 373 GC cases and 
1,332 controls. After exclusion of eight cases and 48 controls 
whose DNA was not amplified or had a genotyping call rate 
lower than 80%, the final analysis was performed on 365 GC 
cases and 1,284 matched controls (Espinosa‐Parrilla et al., 
2014) (Table 1). Regarding the localization of tumors, 29.3% 
were in the cardia or gastroesophageal junction, 49.6% were 
noncardia, 1.6% presented a mixed localization, and 19.5% 
were unspecified; as for the histological type, 34.5% were 
intestinal, 35.1% were diffuse, 2.2% were mixed, and 28.2% 
were unspecified (Table 1).
2.3 | SNV selection, genotyping, quality 
control, and data filtering
We selected a panel of 29 non‐monomorphic SNVs located 
in different functional regions of 30 human miRNAs in-
cluding all SNVs (dbSNP version 126) located on miRNA 
genes (miRBase release 13.0) that were known at the mo-
ment of the design of the study (Table S1). Genotyping of 
these SNVs was included in a panel of 1,536 SNVs described 
in detail elsewhere (Sala et al., 2012). Briefly, genomic 
DNA was extracted from buffy coat and genotyped at the 
Spanish National Genotyping Centre (CEGEN) by use of the 
Illumina BeadStation Platform and GoldenGate Technology 
(Illumina, San Diego, CA), according to the manufacturer's 
T A B L E  1  Main characteristics of the gastric cancer cases and controls analyzed
Cases Controls
N (%) N (%)
Sex Male 214 (58.6%) 759 (59.1%)
Female 151 (41.4%) 525 (40.9%)
Anatomical subtype of gastric 
cancer
Cardia 107 (29.3%) – –
Non‐cardia 181 (49.6%) – –
Mixed 6 (1.6%) – –
Unknown 71 (19.5%) – –
Histological subtype of gastric 
cancer
Intestinal 126 (34.5%) – –
Diffuse 128 (35.1%) – –
Mixed 8 (2.2%) – –
Unknown 103 (28.2%) – –
Mean (Sd) Mean (Sd)
Age at recruitment (years) 58.4 (7.9) 58.4 (7.69)
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protocols. In addition to the internal genotyping controls, 
~5% of the samples (n = 100) were genotyped in duplicate 
with overall agreement of 99.2% (Sala et al., 2012). Among 
the miRNA SNVs selected for the study, eight were excluded 
from the analysis because of technical genotyping problems 
(Table S1). The total number of SNVs successfully geno-
typed and available for analysis was therefore 21 (Table 2). 
As previously described (Espinosa‐Parrilla et al., 2014), de-
viation from Hardy–Weinberg equilibrium (HWE) was es-
tablished at p < 10−4 (Fisher exact test). According to this 
criterion, none of the analyzed SNVs deviated from HWE 
among controls (Table S1). In all cases significance from 
deviation was above 0.05 and only one SNP (rs10505168 
in MIR2053), which was not associated with GC, showed a 
p ≤ 0.05 (p = 0.008).
2.4 | Statistical analyses
As previously described, odds ratios (ORs) and 95% confidence 
intervals (95% CIs) were estimated for general GC as well as 
for its anatomical and histological subtypes using uncondi-
tional logistic regression adjusted by the matching variables 
gender, age, and country using the SNVassoc R package and 
applying a gene‐based 1000‐permutation test on the log‐addi-
tive model to account for multiple testing of the different SNPs 
analyzed in each miRNA gene region (Espinosa‐Parrilla et al., 
2014). Other risk factors for GC such as Helicobacter pylori 
infection, smoking and some other lifestyle and dietary factors 
independent of the genetic variants were not included in the 
models to retain maximal statistical power. The possibility of 
population stratification was considered and excluded as previ-
ously detailed (Sala et al., 2012).
2.5 | miRNA cloning
A genomic region of 521 bp including the 83 bp of the precur-
sor molecule of MIR938 (RefSeq: NR_030634.1) and at least 
100 bp at the 5′ and 100 bp at the 3′ flanking regions was am-
plified from human DNA samples using the forward primer: 
5′ cacacacaAGATCTCCAAATCATTCTGGCAGTGA3′ 
and reverse primer: 5′‐cacacacaCTGCAGTTCATTGCTT-
GTTGGGATCA‐3′. PCR fragments were cloned into the 
pmR‐ZsGreen1 vector (Clontech; Mountain View, CA) 
through PstI and BglIl restriction sites.
T A B L E  2  Main characteristics of the miRNA SNVs analyzed
SNV miRNA Gene Chromosome MAF Controls MAF Cases Location
Alleles (major/
minor) Global Fst
rs41291179 MIR216A 2 0.053 0.047 precursor A/T 0.1068
rs13186787 MIR1294 5 0.002 0.003 precursor A/G 0.0188
rs2910164 MIR146A 5 0.240 0.229 seed C/G 0.1012
rs41274239 MIR96 7 0.004 0.003 precursor A/G 0.0010
rs2114358 MIR1206 8 0.395 0.358 precursor T/C 0.0302
rs10505168 MIR2053 8 0.280 0.274 precursor A/G 0.0768
rs11259096 MIR1265 10 0.048 0.054 precursor T/C 0.2416
rs17091403 MIR2110 10 0.102 0.084 precursor C/T 0.031
rs4919510 MIR608 10 0.191 0.178 mature C/G 0.1406
rs12416605 MIR938 10 0.258 0.248 seed C/T 0.2635
rs11020790 MIR548L 11 0.013 0.007 precursor C/T 0.1503
rs7311975 MIR1178 12 0.028 0.026 seed T/C 0.3701
rs11614913 MIR196A2 12 0.394 0.410 mature C/T 0.2026
rs2289030 MIR492 12 0.058 0.047 precursor C/G 0.1107
rs11844707 MIR1185‐2 14 0.001 0.000 precursor G/A 0.2655
rs6505162 MIR423 17 0.461 0.452 precursor A/C 0.3750
rs17759989 MIR633 17 0.029 0.022 precursor A/G 0.0410
rs895819 MIR27A 19 0.320 0.310 precursor T/C 0.0412
rs3746444 MIR499A 20 0.192 0.185 seed T/C 0.0000
rs3746444 MIR499B 20 0.192 0.185 mature A/G 0.0000
rs4822739 MIR548J 22 0.051 0.049 precursor C/G 0.0613
rs5965660 MIR888 X 0.187 0.218 precursor T/G NA
Abbreviations: Fst, fixation index; MAF, minor allele frequency.
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2.6 | miRNA transfection experiments
For RT‐qPCR experiments, HeLa cells were grown as previ-
ously described and scaled to 1.8 × 105 cells/well in 12‐well 
plates (Lopez‐Valenzuela et al., 2012). After 24 hr, cells were 
double‐transfected with Lipofectamine 2000 (Invitrogen; 
Carlsbad, CA) and 0.75 µg of DNA with the plasmid con-
structions carrying either one or the other allelic variant of the 
studied miRNAs, plus a nonhuman miRNA that was used as 
a control for normalization of transfection. For transcriptome 
analyses 4.5 × 105 cells were grown in 6‐well plates and after 
24  hr, scaled amount of DNA was single‐transfected with 
only one of the above described constructs. Transfections 
were stopped at 24 hr for both RT‐qPCR expression and tran-
scriptome analysis, and 1 ml/well of QIAzol Lysis Reagent 
(QIAGEN; Venlo, Netherlands) was used for total RNA 
extraction using miRNeasy Mini Kit (QIAGEN; Venlo, 
Netherlands). Three and four independent experiments were 
performed for transcriptome and RT‐qPCR experiments, re-
spectively. Each experiment included three technical repli-
cates in all cases.
2.7 | Expression analysis by real‐time 
quantitative reverse transcription polymerase 
chain reaction (RT‐qPCR)
MiRNA expression analyses were performed by RT‐
qPCR starting from 300  ng of total RNA from transfected 
cells by using the specific MIR938 forward primer: 5′‐ 
CAGTGCCCTTAAAGGTGA‐3′ and MIR938 reverse 
primer 5′‐CAGTTTTTTTTTTTTTTTACTGGGT‐3′. 
Primers design and RT‐qPCR protocol were performed as 
previously described (Balcells, Cirera, & Busk, 2011; Gallego 
et al., 2016), using LightCycler® 480 SYBR Green I Master 
(Roche Diagnostics; Rotkreuz, Switzerland) following man-
ufacturer's protocol. Standard curves were calculated by 
pooling samples from transfection experiments. Comparison 
of the expression levels between the two MIR938 variants 
was performed from RT templates (30x) by quantifying the 
relative expression ratio of the studied miRNAs based on the 
efficiency and on the quantification of cycle deviation (ΔCp) 
between the two variants, and comparing versus the refer-
ence miRNA MIR25 as previously described (Gallego et al., 
2016).
2.8 | Whole‐Genome expression analyses in 
HeLa cells using beadchip microarrays
RNA samples from three independent transfection experi-
ments in HeLa cells were used for microarray expression ex-
periments in Agilent SurePrint G3 Human Gene Expression 
microarrays (8×60k), starting from 300  ng of total RNA. 
Data were analyzed using the Array File Maker (AFM) 4.0 
software package (Array File Maker; Stanford, CA). We 
considered genes deregulated when comparing each miRNA 
allelic variant versus the empty construct and differential 
regulation between alleles when comparing each miRNA al-
lelic variant versus the other [nominal p < 0.05 with at least 
1.2 fold change (FC)]. Analyses on the biological functions 
associated with deregulated genes were performed using the 
Ingenuity Pathway Analysis software (IPA, www.ingen uity.
com) and DAVIDGO (http://david.abcc.ncifc rf.gov/home.
jsp).
2.9 | 3′ Untranslated regions (UTR) 
cloning and luciferase activity assay in 
HeLa cells
A fragment of 1,106 bp of the 3′ UTR of CXCL12 (RefSeq: 
NM_000609.6) was amplified by PCR using forward primer 
5′‐acacacgctagcTGTGTTACCTGAAAACACTGTGC‐3′ 
and reverse primer 5′‐acacactctagaAAGGGACAATTTTT-
GTTGATGG‐3′ and cloned into PGL4.13 Promega vector 
containing a Firefly reporter gene, after digestion with XbaI 
enzyme. Co‐transfection experiments have been previously 
described (Lopez‐Valenzuela et al., 2012). Briefly, HeLa 
cells were seeded at 1.3 × 104 cells per well in 96‐well plates 
and co‐transfected 24 hr later with the Firefly reporter con-
structs described above or the empty pGL4.13 vector (24 ng), 
the Renilla reporter plasmid pGL4.75 (3  ng), and 10  nM 
miRNA mimic for the mature miRNAs containing either the 
T or C alleles of rs12416605:C>T, and the negative control 
C2 (Dharmacon; Lafayette, CO), using Lipofectamine 2000 
(Invitrogen; Carlsbad, CA). Activities of Firefly and Renilla 
luciferases were measured 24  hr after transfection using 
Dual‐Glo Luciferase assay system (Promega; Fitchburg, 
WI). Relative reporter firefly luciferase activity was obtained 
by normalization to the Renilla luciferase activity. To correct 
for vector‐dependent unspecific effects, each relative reporter 
activity was normalized to the empty vector co‐transfected 
with the corresponding miRNA. Results were then compared 
with the mean of the C2 negative control. Each experiment 
was done in triplicate and six independent experiments were 
performed for each miRNA. Statistical significance was de-
termined using Student's t test (p < 0.05).
2.10 | Target gene prediction analysis
Potential target genes for MIR938 allelic variants were pre-
dicted using the PITA (Probability of Interaction by Target 
Accessibility) algorithm (Kertesz, Iovino, Unnerstall, Gaul, 
& Segal, 2007). Minimum accessibility energy score (ΔG) 
and the energy‐based score for microRNA‐target interactions 
(ΔΔG) were calculated for all described 3′ UTRs of human 
RefSeq genes and either the MIR938 C or T alleles. A tran-
script was considered as a predicted target when ΔΔG ≤ −8.
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3 |  RESULTS
3.1 | Association of miRNA SNVs with GC 
risk and tumor subtype
To analyze the possible association between gastric adeno-
carcinoma and putative functional SNVs located in miRNAs, 
we genotyped a set of 21 selected SNVs: 15 located in the 
precursor region, outside of the mature miRNA; two in the 
mature region, outside the seed miRNA; three in the seed 
miRNA region; and one SNV, rs3746444:T>C, that was lo-
cated in the seed of MIR499A and in the mature MIR499B, 
since both miRNA genes overlap in sense and antisense 
strands of the same genomic region (Table 2).
Next, we investigated if there were miRNA SNVs 
significantly associated with GC and its subtypes in 365 
incident GC cases with different histological and adeno-
carcinoma location phenotypes matched to 1,284 controls 
from de EPIC cohort (Table 1). Results of the association 
analyses under the log‐additive model are shown in Table 
3. The strongest association was found for rs2114358:T>C 
in the precursor MIR1206, which appeared inversely asso-
ciated with the risk of the non‐cardia localization of the 
adenocarcinoma (per allele OR  =  0.73, 95% CI  =  0.58–
0.93, p  =  0.0093) but not for the cardia localization. 
Additionally, rs3746444:T>C in the mature MIR499A and 
seed of MIR499B was found inversely associated only with 
the risk of the cardia localization of the adenocarcinoma 
(per allele OR = 0.64, 95% CI = 0.42–0.98, p = 0.0308). 
As for the histological subtypes, rs12416605:C>T in the 
seed of MIR938, appeared inversely associated with the 
risk for the diffuse subtype of GC (per allele OR  =  0.7, 
95% CI = 0.51–0.97, p = 0.0281) but not for the intestinal 
one (Table 3). These results are suggestive of a protective 
effect against GC for the minor alleles of all three SNVs (C 
rs2114358, C rs3746444, and T rs12416605).
Analyses by other inheritance models (codominant, dom-
inant, and recessive) indicated that the only association that 
was stronger with a model different from the log‐additive was 
that of rs3746444:T>C with the cardia phenotype, which was 
better explained by the dominant model (OR  =  0.58, 95% 
CI = 0.36–0.94, p = 0.0210).
3.2 | rs12416605:C>T 
affects the expression of MIR938 and several 
gene regulatory pathways
rs2114358 in MIR1206, and rs3746444:T>C in MIR499 have 
already been shown to affect the dosage of the corresponding 
miRNAs by altering either their biogenesis or stability (Kim, 
Prokunina‐Olsson, & Chanock, 2012; Torruella‐Loran et al., 
2016). Conversely, no studies have been conducted to ana-
lyse the functional effect of rs12416605:C>T in MIR938. We 
therefore investigated if there were differences in miRNA ex-
pression or in gene regulation between both rs12416605:C>T 
MIR938 alleles that could explain their genetic association 
with GC.
To test the effect of rs12416605:C>T in MIR938 expres-
sion, we cloned both miRNA alleles and co‐transfected them 
in HeLa cells (after confirming that these cells had undetect-
able levels of endogenous MIR938) together with a control 
miRNA for normalization of transfection (Figure 1a). After 
measuring MIR938 expression by RT‐qPCR, we observed 
F I G U R E  1  Effect of rs12416605:C>T on MIR938 expression. (a) Outline of the miRNA co‐transfection experiments in HeLa cells 
using the pmR‐ZsGreen1 vector (Clontech) containing either one of the two MIR938 rs12416605 alleles or a nonhuman control miRNA used 
for normalization of transfection. (b) Box‐plot showing differences in the expression levels (ΔCt), measured by qPCR for the C and T MIR938 
rs12416605 alleles after co‐transfection experiments, related to the control reference miRNA. Each experiment was done in triplicate and four 
independent experiments were performed. Data reported here are the means ± SEM of all experiments performed. A significant reduction between 
the expression of the C and T alleles was found (p < 0.05, Student's t test)
(b)(a)
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that the rs12416605 C allele was 1.49 times more expressed 
than the T allele (Student t test, p < 0.05) indicating that this 
variant in MIR938 may be affecting the final expression of 
the miRNA (Figure 1b).
In addition to differences in the expression levels between 
the rs12416605 C and T alleles, this nucleotide substitution 
could also change the spectrum of miRNA target genes; 
therefore, we investigated which genes could be regulated by 
each miRNA allelic variant through miRNA overexpression 
experiments and transcriptome analyses. After transfection of 
both miRNA alleles in HeLa cells, we selected those tran-
scripts statistically significant up‐ or downregulated with 
respect to the control miRNA, using a relaxed cutoff value 
(p < 0.05, over a 1.2 FC). The MIR938 C allele deregulated 
2,045 transcripts, whereas the T allele deregulated 1,825 
transcripts. Among those, 829 were deregulated by both the 
alleles (this represents 40.5% and 45.5% of the transcripts 
deregulated by the C and T allele, respectively), indicating 
that about 50% of the transcripts were exclusively regulated 
by each rs12416605:C>T allele. Next, we used Ingenuity 
Pathway Analysis software to analyse the functions associ-
ated with the genes deregulated after overexpression of each 
MIR938 allelic variant. Both the alleles presented cancer as 
their top disease associated with their deregulated genes. 
Interestingly, variant C but not variant T presented gastro-
intestinal disease among the top five diseases to which their 
deregulated genes were associated (Table S2). According to 
cancer as the top associated disease and among the top 10 
upregulated and downregulated genes, there were several 
genes that are implicated in the etiology of gastric cancer, 
such as the protein tyrosine phosphatase nonreceptor type 11 
(PTPN11) (Liu et al., 2015) or the Fibroblast Growth Factor 
1 (FGF1) (Zhuo et al., 2016); (Table 4). Remarkably, most of 
the top 10 downregulated transcripts (8 out of 10) but none of 
the top 10 upregulated transcripts were common deregulated 
genes between the two rs12416605:C>T alleles (Table 4).
3.3 | The chemokine CXCL12 is regulated 
by MIR938 in an allele‐dependent manner
We next investigated if there were cancer‐related genes dif-
ferentially regulated by the MIR938 alleles that could be ex-
clusive direct target genes of only one of the rs12416605:C>T 
allelic variants of MIR938. We used PITA algorithm to pre-
dict MIR938 C and MIR938 T targets among the whole set 
of differentially regulated transcripts that were related to 
T A B L E  4  Top 10 deregulated genes by MIR938 rs12416605:C>T alleles compared to the empty vector control and ordered from the highest 
to the lowest fold change (FC)
MIR938 C MIR938 T
Gene FC p values Gene FC p values
Top 10 up‐regulated genes TSPAN19 4.44 3.36E‐02 HPGDS 4.39 1.30E‐03
C18orf34 3.74 5.17E‐03s TRPA1 3.60 8.12E‐04
SLC4A5 3.56 4.79E‐03 SORBS1 3.51 8.07E‐04
CHD6 3.33 4.65E‐02 PEX5L‐AS2 3.39 4.82E‐06
BC015129 3.14 5.30E‐04 OR1D5 3.31 2.58E‐03
IL34 3.07 9.48E‐04 SLC23A2 3.26 1.46E‐03
OR5B2 2.93 3.85E‐03 FLJ21408 3.16 2.03E‐07
GRIP1 2.77 3.19E‐03 PRR15L 3.09 3.36E‐03
SRRM4 2.73 2.92E‐02 RBMS3 2.99 2.02E‐03
ABCA8 2.71 2.00E‐02 RNF157 2.95 1.60E‐05
Top 10 down‐regulated 
genes
NKX2‐8 −6.65 1.72E‐03 NKX2‐8 −5.95 3.02E‐03
ZNF730 −5.10 2.00E‐03 ZNF730 −5.00 2.22E‐03
THPO −4.71 1.45E‐03 THPO −4.68 1.51E‐03
MFSD4 −4.27 3.79E‐04 DNAJC3 −3.93 2.53E‐03
PTPN11 −4.13 8.18E‐03 HNF1A −3.85 7.25E‐03
DPCR1 −3.99 1.13E‐02 MFSD4 −3.79 9.88E‐04
HNF1A −3.92 6.52E‐03 FGF1 −3.78 3.40E‐02
MDM1 −3.67 1.02E‐02 PTPN11 −3.74 1.35E‐02
C1orf210 −3.66 1.91E‐03 DPCR1 −3.72 1.58E‐02
CCDC103 −3.62 2.32E‐03 C1orf210 −3.63 2.00E‐03
Note: In grey, common deregulated transcripts to both the alleles.
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cancer according to DAVIDGO (Table S3). Three GC‐re-
lated genes were predicted to be exclusively regulated by 
one of the MIR938 allelic variants: the chemokine receptor 5 
CCR5, the Leptin receptor LEPR, and the chemokine CXCL12 
(Table 5). Among these genes, the one that presented the high-
est difference in the PITA prediction between alleles was the 
CXCL12 chemokine, which showed a predicted target site for 
the rs12416605 C allele (ΔΔG  =  −9.08) whereas any good 
prediction was found for the T allele (ΔΔG = −0.93) (Table 
5, Figure 2a). These differences between MIR938 alleles and 
the fact that CXCL12 is reported to be involved in GC through 
its participation in cell migration and invasion (Cheng et al., 
2017; Izumi et al., 2016; Rubie, Kauffels, Kölsch, Glanemann, 
& Justinger, 2016) led us to investigate the possible interaction 
between CXCL12 and the rs12416605:C>T alleles by means 
of a dual‐luciferase assay in HeLa cells. A luciferase reporter 
pGL4.13 construct, either empty or carrying the 3′UTR of the 
CXCL12, was co‐transfected with the corresponding miRNA 
mimic: MIR938 T, MIR938 C, or a control miRNA. As shown 
in Figure 2b, a statistically significant reduction in the lucif-
erase activity was observed for the rs12416605 C allele of 
MIR938 when co‐transfected with the 3′ UTR of the CXCL12 
compared to both, the control miRNA and the T allelic vari-
ant (p < 0.01, Student's t test). The observed reduction in the 
luciferase activity would be compatible with a 40% repression 
of CXCL12 exclusively by the rs12416605 C allele of MIR938, 
suggesting that differences in the regulation of CXCL12 be-
tween both alleles might be underlying the genetic association 
of GC with the rs12416605 SNV in MIR938 and the protective 
effect found for the T allele against diffuse GC.
4 |  DISCUSSION
Even though changes in the expression of miRNAs have been 
largely associated with GC and impaired miRNA expression 
may be related to genetic variation in their sequences, still 
there is lack of evidence explaining the real contribution of 
miRNA genetic variants to GC pathology. In the present 
study, we evaluated several putative allelic variants in func-
tional miRNA regions as candidate susceptibility factors to 
GC by means of association studies and demonstrated a pos-
sible causative effect for at least one of these variants using a 
functional approach.
We identified three common genetic variants in miRNA 
genes that associated with GC. One of them, rs3746444:T>C 
in MIR499, has largely been reported to be associated with 
cancer and has further been suggested as having a role in the 
GC etiology (Ahn et al., 2013; Chen, Yang, Chaugai, Wang, 
& Wang, 2014). In the present work, we identified the C 
allele of this SNV as a protective factor against the cardia 
GC subtype under the log‐additive and dominant models, 
which is partially in agreement with a recent meta‐analysis 
study in which rs3746444:T>C was reported to be associ-
ated with GC in Asian but not European populations (Chen 
et al., 2014). Even though this last study did not find asso-
ciation in Europeans, another study supports our finding by 
reporting association of this SNV with another cancer type 
in populations of European origin (Nikolić et al., 2015). 
Furthermore, we have recently shown that the two alleles of 
rs3746444:T>C may influence the processing and expres-
sion of MIR499A and MIR499B, which ultimately may be 
affecting the regulation of their target genes in a dosage and 
allele‐dependent manner (Torruella‐Loran et al., 2016). More 
importantly, we showed that the T allele of MIR499A caused 
a significant repression of the cadherin CDH1 and the cell 
adhesion molecule CLH1, which could be associated with a 
malignant behavior of the T allele and, consequently, with the 
protective effect found for the C allele against GC.
Another of the SNVs that we found associated with GC 
was rs2114358:T>C, in the precursor molecule of MIR1206. 
Even though this miRNA is in the cancer risk loci 8q24.2, 
this is the first report of a genetic association of MIR1206 
with cancer. Significantly, a previous report demonstrated 
an effect of rs2114358:T>C in the biogenesis of the mature 
miRNA forms (Kim, Prokunina‐Olsson, et al., 2012), and 
several genes involved in GC such us FGF2 and TP53INP1 
appear as targets of MIR1206 in miRTarBase. Given the loca-
tion of this variant in the precursor region outside the mature 
miRNA molecule, the functional effect of rs2114358:T>C 
might be through allele‐specific variation of miRNA expres-
sion rather than alteration in the spectrum of target genes.
The third SNV associated with GC was rs12416605:C>T 
in the seed of MIR938. Interestingly, a previous study reported 
the association of GC with another SNV (rs2505901) in the 
MIR938 primary precursor molecule as well as another vari-
ant (rs2275913) in IL17A, a MIR938‐targeted gene (Arisawa 
et al., 2012). To investigate the possible contribution of 
rs12416605:C>T to GC, we analyzed the effect of both the 
T A B L E  5  Cancer‐related genes predicted to be differentially 
regulated by MIR938 rs12416605:C>T alleles according to PITA 
target site predictions
Gene Alleles
Best Pita Score 
ΔΔG








CCR5 (C‐C chemokine receptor 5) C −5.79
T −12.81
LEPR (Leptin receptor) C −4.77
T −11.81
Note: The best Pita score (energy for microRNA‐target interaction, ΔΔG) for 
each allele is shown. Relevant Pita score scores are indicated in bold face.
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alleles in the expression levels of MIR938. Remarkably, sta-
tistically significant differences were observed between the 
expression levels of each miRNA variant: The C variant of 
MIR938 was 1.49 times more expressed than the T variant. 
Besides the alteration in the expression levels of MIR938, this 
MIR938 variant was also predicted to regulate several gas-
tric cancer‐related genes in an allele‐dependent manner. For 
instance, the CASP8 and FADD‐Like Apoptosis Regulator 
(CFLAR) gene has strong ΔΔG PITA scores, particularly for 
the C rs12416605 allele (−15.51 and −11.4 for the C and T 
alleles, respectively, Table 5). CFLAR is a gene that encodes 
the FLICE‐like inhibitory protein (c‐FLIP) that acts as an in-
hibitor of the Fas‐mediated apoptosis and helps tumor cells 
to escape from TRAIL‐mediated apoptosis, hence promoting 
metastasis and tumor progression (Olsson & Zhivotovsky, 
2011; Zhang et al., 2004; Zhou et al., 2004). Several SNVs 
in the CFLAR gene have been associated with GC in Chinese 
populations (Hyland et al., 2004) reinforcing a role for CFLAR 
in GC. Moreover, CFLAR mRNA and its protein were found 
highly expressed in gastric adenocarcinomas compared with 
normal gastric mucosa tissue in patients of Chinese origin 
stressing the importance of CFLAR expression regulation in 
the pathophysiology of GC (Zhou et al., 2004), which may 
be mediated by MIR938. In addition to CFLAR, which might 
be regulated by both allelic variants of MIR938, we found at 
least three other genes that were predicted as exclusive targets 
of only one of the MIR938 variants and that are known to 
play important roles in GC (Table 5). For instance, the C‐C 
chemokine receptor 5 (CCR5) and the Leptin receptor (LEPR) 
are related to GC (Chang, Du, Zhao, Ma, & Cao, 2014; Kim, 
Chin, et al., 2012; Shi et al., 2014), and were predicted to be 
regulated exclusively by the T allele. Leptin and its recep-
tor are known to play a role in Helicobacter pylori infection 
(Azuma et al., 2001), and a polymorphism in LEPR has been 
associated with GC risk in Korean populations (Kim, Chin, et 
al., 2012). Similarly, CCR5 was predicted as targeted solely by 
the T MIR938 allele. In this context, the expression of CCR5 
has been found to favor metastasis in GC patients (Cao et al., 
2011) and thereby, repression of the CCL5/CCR5 axis has 
been suggested as a possible therapeutic strategy against GC 
progression (Aldinucci & Casagrande, 2018), which would be 
compatible with a protective effect of the T MIR938 allele me-
diated by its putative repression of CCR5. Finally, the chemo-
kine CXCL12 was predicted to be regulated exclusively by the 
MIR938 C allelic variant with the best ΔΔG PITA score of 
−9.08. CXCL12 has been shown to have a critical role in GC 
promoting cell migration and invasion, although a controver-
sial participation for CXCL12 in metastasis has been reported: 
several authors show that absence of CXCL12 expression 
might lead to GC metastasis whereas some others suggest 
that CXCL12 overexpression promotes cell invasion (Cheng 
et al., 2017; Izumi et al., 2016; Rubie et al., 2016; Zhi et al., 
F I G U R E  2  Allele‐specific regulation 
of the chemokine CXCL12 by MIR938. (a) 
Sequence alignment between the MIR938 
rs12416605 C and T alleles and the CXCL12 
mRNA showing the PITA predicted target 
site and ΔΔG PITA scores for both alleles 
on this site. (b) Results of the luciferase‐
reporter assay testing the interaction 
between MIR938 rs12416605 C and T 
alleles and the 3′UTR of the CXCL12 in 
HeLa cells. Ratios of the Firefly and Renilla 
luciferase luminescence are presented 
after normalization to the empty plasmid 
pGL4.13. Each experiment sswas done in 
triplicate and six independent experiments 
were performed. Data reported here are the 
means ± SEM of all experiments performed. 
A significant reduction in the luciferase 
activity between both the alleles and 
between the C allele and the control miRNA 
was found (*, p < 0.01, Student's t‐test)
(a)
(b)
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2012). In this context, the CXCL12/CXCR4 axis has been 
proposed as a promising therapeutic target for advanced GC 
(Xue, Mao, Ren, & Chu, 2017). The here observed repression 
of about 40% of this chemokine by the C but not the T allele, 
together with the increased expression of MIR938 related to 
the rs12416605 C allele, might cause an amplified downregu-
lation of CXCL12 in C carriers that could be associated with a 
promotion of GC metastasis. This would agree with our find-
ing of the T allele as a protective factor and with the finding 
of a higher frequency of the T allele in European compared 
with Asian populations (29% vs. 2%, 1,000 genomes data), 
which is reflected by a high‐global fixation index (Fst) for this 
SNV (0.2635 for the global Fst, Table 2) and in agreement 
with Asian populations having a higher predisposition to GC.
In conclusion, we replicated a previously described as-
sociation of MIR499 rs3746444:T>C with GC in European 
populations and identified two new unreported associations 
of miRNA SNVs with GC: rs12416605:T>C in MIR938 and 
rs2114358:T>C in MIR1206. We showed a significant differ-
ence in MIR938 expression between rs12416605 alleles and 
suggested that the protective effect of the T MIR938 allele 
against diffuse GC could be mediated by the lack of repres-
sion of the chemokine CXCL12. These findings strongly sug-
gest a role for CXCL12 posttranscriptional regulation in the 
development of GC and as a candidate regulatory pathway for 
anticancer therapies.
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